Published in PLoS One on September 11, 2014
Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes. PLoS One (2016) 1.41
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis (2014) 1.09
The March Toward Malaria Vaccines. Am J Prev Med (2015) 0.96
The march toward malaria vaccines. Vaccine (2015) 0.95
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. J Infect Dis (2016) 0.91
Recent advances in recombinant protein-based malaria vaccines. Vaccine (2015) 0.91
Malaria vaccine clinical trials: what's on the horizon. Curr Opin Immunol (2015) 0.80
Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults. Malar J (2015) 0.80
Tuberculosis vaccine development: Shifting focus amid increasing development challenges. Hum Vaccin Immunother (2015) 0.80
Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity". Vaccine (2015) 0.79
A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens. J Immunol (2016) 0.79
Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice. Vaccine (2016) 0.78
Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8(+) T Cells. J Immunol (2017) 0.78
Analysis of the immune response of a new malaria vaccine based on the modification of cryptic epitopes. Parasitol Res (2016) 0.77
A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine. PLoS One (2016) 0.76
Discriminating Protective from Nonprotective Plasmodium-Specific CD8+ T Cell Responses. J Immunol (2016) 0.75
Profiling the host response to malaria vaccination and malaria challenge. Vaccine (2015) 0.75
Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming. Hum Vaccin Immunother (2015) 0.75
Polyfunctional and IFN-γ monofunctional human CD4(+) T cell populations are molecularly distinct. JCI Insight (2017) 0.75
Complex Minigene Library Vaccination for Discovery of Pre-Erythrocytic Plasmodium T Cell Antigens. PLoS One (2016) 0.75
Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malaria. Malar J (2016) 0.75
Cryopreservation-related loss of antigen-specific IFNγ producing CD4(+) T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. Vaccine (2017) 0.75
A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP142 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge. Clin Vaccine Immunol (2017) 0.75
Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy. Front Immunol (2017) 0.75
Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet (2012) 17.62
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 11.65
T cell exhaustion. Nat Immunol (2011) 11.08
Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med (1997) 8.59
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (2013) 4.60
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis (2008) 4.47
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51
HLA class I supertypes: a revised and updated classification. BMC Immunol (2008) 3.47
A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem (2003) 2.84
Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics (2008) 2.69
Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol (2008) 2.63
Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A (2008) 2.62
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A (1994) 2.58
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
Circumsporozoite proteins of malaria parasites. Cell (1985) 2.45
Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun (2009) 2.08
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol (2005) 2.03
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine (2002) 1.97
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun (2013) 1.95
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med (2004) 1.70
Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med (2011) 1.66
Genetic control of immunity to Plasmodium yoelii sporozoites. J Immunol (1989) 1.66
Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol Rev (2008) 1.64
Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A (2001) 1.63
Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe (2011) 1.61
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One (2012) 1.58
CD8+ T effector memory cells protect against liver-stage malaria. J Immunol (2011) 1.55
Immune response to pre-erythrocytic stages of malaria parasites. Curr Mol Med (2006) 1.50
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One (2013) 1.47
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses (2009) 1.36
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One (2011) 1.32
The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology (2009) 1.29
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine (2011) 1.25
Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther (2006) 1.25
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One (2011) 1.25
HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol (2011) 1.21
Malaria elimination: worthy, challenging, and just possible. Lancet (2010) 1.21
Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One (2012) 1.16
Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells. PLoS One (2011) 1.15
Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol (2012) 1.12
Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol (2012) 1.05
Memory CD8+ T cell responses expand when antigen presentation overcomes T cell self-regulation. J Immunol (2008) 1.04
Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS One (2009) 1.01
Unique transcriptional profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites. Genes Immun (2013) 0.98
Early self-regulatory mechanisms control the magnitude of CD8+ T cell responses against liver stages of murine malaria. J Immunol (2003) 0.96
Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination. Front Immunol (2012) 0.96
Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malar J (2010) 0.96
Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malar J (2013) 0.95
Memory CD8 T cells specific for plasmodia liver-stage antigens maintain protracted protection against malaria. Front Immunol (2012) 0.94
Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells. Vaccine (2009) 0.94
Qualitative and quantitative analysis of adenovirus type 5 vector-induced memory CD8 T cells: not as bad as their reputation. J Virol (2013) 0.91
Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol. Infect Immun (2011) 0.91
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum Vaccin Immunother (2013) 0.90
DNA vaccination: the answer to stable, protective T-cell memory? Curr Opin Immunol (2003) 0.81
Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. Immunol Lett (1990) 0.80
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One (2013) 1.47
The Ontology for Biomedical Investigations. PLoS One (2016) 0.94
Analysis of Human RSV Immunity at the Molecular Level: Learning from the Past and Present. PLoS One (2015) 0.75
Citrullination only infrequently impacts peptide binding to HLA class II MHC. PLoS One (2017) 0.75